A single blinded randomised, crossover, individual comparison on cardiac performance of xenon vs. sevoflurane inhalation in humans undergoing coronary artery bypass grafting

A single blinded randomised, crossover, individual comparison on cardiac performance of xenon vs. sevoflurane inhalation in humans undergoing coronary artery bypass grafting - A study on effects of xenon inhalation in humans undergoing CABG; part I

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON31231

Enrollment

Registered

2007-10-16

Start date

2007-10-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CABG

Interventions

Patients in Group A will at first receive 1 MAC Sevoflurane in O2/Air, followed after a 20-min period by measuring the contractility index using TOE. Then, Sevoflurane will be washed out and 65% xen

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Age range: 18 years and older, Patients who have to undergo elective cardiac surgery (CABG with or without valve surgery), Written informed consent

Exclusion criteria

Exclusion criteria: Age range:

Design outcomes

Primary

Measure	Time frame
The primary endpoint is defined as the change in cardiac performance, defined as cardiac function index (PICCO) and contractility index (TEE).	—

Secondary

Measure	Time frame
-	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)